High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients

Stearoyl-CoA desaturase 1 (SCD1) is an essential regulator of fatty acid synthesis. We have previously shown that overexpression of SCD1 increases the growth of breast cancer cell lines. The purpose of this study was to determine the relationship between SCD1 expression level and clinical-pathologic characteristics and survival of patients with breast cancer. Fine-needle aspirates were collected from the primary tumors of 250 patients with stage I–III breast cancer. Demographic and clinical characteristics including patient age, ethnicity, and menopausal status and tumor clinical stage, grade, and subtype were reviewed. SCD1 expression was analyzed using reverse-phase protein arrays. Samples were divided into high or low SCD1 expression levels based on a cut-off determined from martingale residual plots and regression tree analysis. SCD1 levels were significantly higher in tumors from patients >50-years old compared to patients ≤50-years old and were lower in triple-negative (estrogen/progesterone receptor-negative and human epidermal growth factor receptor-2-negative) breast cancers than other tumor subtypes. After adjusting for patient age, tumor subtype, tumor grade, and clinical stage, we found that patients with primary breast cancers expressing high SCD1 levels had significantly shorter relapse-free survival (RFS) (P = 0.0140) and overall survival (OS) (P = 0.039) in multivariable analysis. We conclude that SCD1 expression varies by breast cancer subtype and that high levels of SCD1 expression are associated with significantly shorter RFS and OS in multivariable analysis. Future studies are needed to define the role of SCD1 in the malignant phenotype of breast cancer and to evaluate the potential for SCD1 as a therapeutic target.

[1]  B. Yandell,et al.  Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Sham,et al.  Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[3]  F. Foufelle,et al.  SREBP-1c Transcription Factor and Lipid Homeostasis: Clinical Perspective , 2007, Hormone Research in Paediatrics.

[4]  J. Ntambi.  Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. , 1999, Journal of lipid research.

[5]  M. Bonini,et al.  Inhibition of StearoylCoA Desaturase-1 Inactivates Acetyl-CoA Carboxylase and Impairs Proliferation in Cancer Cells: Role of AMPK , 2009, PloS one.

[6]  Brendan Connolly,et al.  Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry. , 2008, Analytica chimica acta.

[7]  B. Spiegelman,et al.  Identification of Conserved cis-Elements and Transcription Factors Required for Sterol-regulated Transcription of Stearoyl-CoA Desaturase 1 and 2* , 1999, The Journal of Biological Chemistry.

[8]  L. Zhang,et al.  Human stearoyl-CoA desaturase: alternative transcripts generated from a single gene by usage of tandem polyadenylation sites. , 1999, The Biochemical journal.

[9]  M. Greig,et al.  Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity. , 2008, Analytica chimica acta.

[10]  X. Deng,et al.  Dysregulation of sterol regulatory element binding protein-1c in livers of morbidly obese women is associated with altered suppressor of cytokine signaling-3 and signal transducer and activator of transcription-1 signaling. , 2010, Metabolism: clinical and experimental.

[11]  Key role of the ERK1/2 MAPK pathway in the transcriptional regulation of the Stearoyl-CoA Desaturase (SCD1) gene expression in response to leptin , 2010, Molecular and Cellular Endocrinology.

[12]  R. A. Igal.  Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. , 2010, Carcinogenesis.

[13]  K. Mak,et al.  Leptin enhances α1(I) collagen gene expression in LX‐2 human hepatic stellate cells through JAK‐mediated H2O2‐dependent MAPK pathways , 2006, Journal of cellular biochemistry.

[14]  K. Dahlman-Wright,et al.  Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice. , 2008, American journal of physiology. Endocrinology and metabolism.

[15]  R. A. Igal,et al.  Inhibition of Stearoyl-CoA Desaturase 1 expression in human lung adenocarcinoma cells impairs tumorigenesis. , 2008, International journal of oncology.

[16]  J. Fargnoli,et al.  Cancer Cell Dependence on Unsaturated Fatty Acids Implicates Stearoyl-CoA Desaturase as a Target for Cancer Therapy , 2011, Molecular Cancer Research.

[17]  Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC Study. , 2008, American journal of epidemiology.

[18]  M. Gariboldi,et al.  Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. , 2002, Carcinogenesis.

[19]  J. Lampe,et al.  Erythrocyte fatty acids and breast cancer risk: a case-control study in Shanghai, China. , 2007, The American journal of clinical nutrition.

[20]  M. Makuuchi,et al.  Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. , 2005, European journal of cancer.

[21]  K. Dahlman-Wright,et al.  Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: a possible mechanism is through direct regulation of signal transducer and activator of transcription 3. , 2006, Molecular endocrinology.

[22]  S. Fesik,et al.  Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. , 2007, Cancer research.

[23]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[24]  E. Riboli,et al.  Fatty acid composition in serum phospholipids and risk of breast cancer: A prospective cohort study in northern sweden , 2007, Lipids.

[25]  N. Habib,et al.  Partial characterization of a cDNA for human stearoyl‐CoA desaturase and changes in its mRNA expression in some normal and malignant tissues , 1994, International journal of cancer.

[26]  F. Berrino,et al.  Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. , 2001, Journal of the National Cancer Institute.

[27]  J. Ntambi,et al.  Nuclear factor 1 is essential for the expression of stearoyl-CoA desaturase 1 gene during preadipocyte differentiation. , 1998, Biochimica et biophysica acta.

[28]  C. Couet,et al.  Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinoma , 1991, Breast Cancer Research and Treatment.

[29]  Anne E Carpenter,et al.  mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway , 2011, Cell.

[30]  D. Hess,et al.  Inhibition of StearoylCoA Desaturase Activity Blocks Cell Cycle Progression and Induces Programmed Cell Death in Lung Cancer Cells , 2010, PloS one.

[31]  H. Enoch,et al.  Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid. , 1976, The Journal of biological chemistry.

[32]  S. Culine,et al.  Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice , 2010, Molecular Cancer Therapeutics.

[33]  Qicheng Ma,et al.  Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.

[34]  G. Mills,et al.  Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer , 2010, Molecular Cancer Therapeutics.

[35]  M. Lane,et al.  Cell-free transcription directed by the 422 adipose P2 gene promoter: activation by the CCAAT/enhancer binding protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Caviglia,et al.  High stearoyl-CoA desaturase protein and activity levels in simian virus 40 transformed-human lung fibroblasts. , 2005, Biochimica et biophysica acta.

[37]  P. Pandolfi,et al.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.

[38]  G. Hortobagyi,et al.  Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Margaret S. Wu,et al.  Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. , 2005, The Journal of clinical investigation.

[40]  G. Mills,et al.  PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors , 2012, Clinical Cancer Research.

[41]  J. Fuscoe,et al.  Detection of early gene expression changes by differential display in the livers of mice exposed to dichloroacetic acid. , 2001, Carcinogenesis.

[42]  B. Cohen,et al.  Modulation of Insulin Activities by Leptin , 1996, Science.

[43]  C. Mounier,et al.  Role of the PI3-kinase/mTor pathway in the regulation of the stearoyl CoA desaturase (SCD1) gene expression by insulin in liver , 2007, Journal of Cell Communication and Signaling.

[44]  K. Dahlman-Wright,et al.  Evidence that oestrogen receptor-α plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver , 2006, Diabetologia.

[45]  J. Ntambi,et al.  Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. , 1989, Genes & development.